The device is now commercially available across 30 European countries, with the first surgical implantation expected in Germany in September 2026.
Clinical trial results published in the New England Journal of Medicine showed 84% of patients regained the ability to read letters, numbers, and words.
Age-related macular degeneration affects more than five million people globally. The macula, the central part of the retina responsible for reading, facial recognition, and detailed vision, progressively deteriorates and leaves patients with a blind spot at the center of their visual field. Until now, there was no treatment that could restore what was lost.
Science Corporation, a clinical-stage neurotechnology company founded by former Neuralink president Max Hodak, has changed that calculus. On July 22, 2026, the company announced that its PRIMA subretinal photovoltaic implant received CE mark certification under the European Union Medical Device Regulation from DEKRA, authorizing commercial sales across the European Economic Area.
First commercial implantation in Germany. September 2026 is the real-world adoption signal.
FDA breakthrough device and humanitarian use device designations. US market access pathway is active.
Reimbursement negotiations with European healthcare providers. Pricing and coverage terms determine addressable market.
Second-generation PRIMA chip and AR-glasses form factor. The technology roadmap extends well beyond the current device.
The Clinical Evidence Behind PRIMA
The PRIMAvera multicenter clinical trial enrolled 38 patients across 17 sites in five countries. Results published in the New England Journal of Medicine demonstrated a mean improvement of 25.5 ETDRS letters, equivalent to more than five lines on a standard visual acuity chart, at 12 months. Eighty percent of patients achieved at least a 0.2 logMAR improvement. Critically, the implant was placed beneath the atrophic macula without reducing patients' residual peripheral natural vision.
PRIMA clinical trial primary endpoint
Patients with geographic atrophy due to AMD who received the PRIMA implant showed a mean gain of 25.5 ETDRS letters at 12 months. 84% reported the ability to read letters, numbers, and words. · New England Journal of Medicine, 2025
The PRIMA system consists of an ultra-thin 2×2 mm wireless subretinal implant paired with specialized glasses. The glasses project near-infrared light onto the implant, which converts it into electrical stimulation signals that activate surviving bipolar cells in the retina. A zoom-in feature allows patients to magnify text. One patient finished a 300-page novel after receiving the implant.
Market Context and Competitive Position
Science Corporation closed a $230 million Series C in March 2026 at a $1.5 billion post-money valuation to fund PRIMA's commercialization and expand clinical trials into additional indications. The round signals that institutional investors see BCIs as an investable category beyond research-stage curiosity.
PRIMA operates in a sparse competitive field. Pixium Vision, the French company that originally developed the technology, transferred the intellectual property to Science Corporation in 2024. Neuralink, where Hodak was a co-founder before leaving in 2021, is pursuing a different technical approach, intracortical electrodes for broader applications, and remains in the clinical-trial phase. Second Sight Medical Products' Argus II, the only other commercially approved retinal implant, was discontinued in 2022. No other device has demonstrated restoration of functional central vision in a peer-reviewed, multicenter trial.
The addressable market is large and growing. AMD-associated GA affects more than 5 million people globally, with prevalence rising as populations age. Currently, no pharmacological treatment exists that can restore lost photoreceptors. The standard of care is limited to slowing disease progression via anti-VEGF injections or complement inhibitors.
The technology: how a photovoltaic retinal implant works
Source: Science Corporation / NEJM, 2025
For decades, losing central vision to this disease meant losing the ability to read, recognize faces, and ultimately losing independence. There was no viable treatment. Now there is.— Max Hodak, CEO and co-founder, Science Corporation
Commercial Path and Reimbursement
The CE mark opens the regulatory gateway but does not guarantee commercial success. Science Corporation has begun country-specific reimbursement applications and clinical site activations across Europe. The first commercial implantation is expected in Germany, where the PRIMAvera clinical trial was conducted. Reimbursement negotiations with healthcare providers will determine the device's real-world addressable market. PRIMA is a surgical implant requiring specialized ophthalmic surgeons and specific patient selection criteria.
In the United States, PRIMA has received both Breakthrough Device designation and Humanitarian Use Device designation from the FDA. These are early-stage regulatory signals that establish a pathway toward US market access, but the FDA has not yet set a timeline for review or approval. The company has launched a patient registry for macular degeneration in preparation for the US submission.
Hodak has been explicit about the business target: "The thing that the space needs is a company making $100 million a year of revenue." European commercial launch, combined with US regulatory progress, forms the two-part strategy to hit that threshold.
What happens to the BCI vision market a year from now?
Probability: 70%. European adoption in Germany plus 2-3 additional countries, combined with US FDA timeline clarity, will produce enough claims data to estimate annualized revenue trajectory.
✅ Arguments for
+ $230M Series C provides multi-year runway for commercialization and US submission
+ NEJM publication provides clinical credibility for reimbursement negotiations
Confirmation criteria: First 100 commercial implants within 12 months of German launch
❌ Arguments against
− The 38-patient trial sample size is small. Real-world complication rates may differ from the pivotal study.
− FDA has not committed to a review timeline. The US pathway is years, not months.
Disconfirmation criteria: No commercial revenue generated within 18 months of CE mark
Development scenarios
🟢 Optimistic scenario (25%)
Implications: Validates BCI as a commercial medical device category, triggers M&A interest from larger medtech firms.
🟡 Base-case scenario (55%)
Implications: Science Corporation remains independent but must raise additional capital before next-generation product cycle.
🔴 Pessimistic scenario (20%)
Implications: Delays BCI commercialization timeline sector-wide. Investors reprice the category risk.
What This Means for the BCI Sector
PRIMA's CE mark matters beyond Science Corporation as a company. It is the first time a BCI device for sensory restoration has crossed the regulatory-commercial threshold in a major market. Every BCI company from Neuralink to Synchron to Precision Neuro now has a reference point for regulatory pathway, clinical evidence standards, and commercial timeline expectations.
Hodak's $100 million revenue target functions as a benchmark for the entire space. If Science Corporation reaches it, the BCI investment thesis shifts from "promising technology" to "viable category." If it falls short, the capital reallocation signal will be equally clear.
